Having trouble accessing articles? Reset your cache.

InterMune sells danoprevir rights to Roche

InterMune Inc. (NASDAQ:ITMN) sold all rights to HCV candidate danoprevir to partner Roche (SIX:ROG; OTCQX:RHHBY) for $175 million in cash.

Read the full 203 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE